Skip to main content
ENGN logo

ENGN · enGene Therapeutics Inc. · Holdings

Track ENGN — free
$1.74 -0.02 (-1.14%) At close · Nov 20
Market Cap
$116.61M
Shares
67.02M
Volume · Nov 20 556.73K Avg daily vol (3M) 1.1M

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 68
Total Value: $97,456,646
Total Shares: 50,777,846

Institutional Ownership Trend

12 quarters

Holder Concentration

Share of 13F common-share value, across 68 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
19.8%
Dec 2023 → Sep 2026 · range 16.4% – 61.2%
+0.7 pts
Top 5
61.3%
Dec 2023 → Sep 2026 · range 48.7% – 98.5%
+1.6 pts
Top 10
81.8%
Dec 2023 → Sep 2026 · range 72.3% – 100.0%
+5.4 pts
HHI
975
Dec 2023 → Sep 2026 · range 700 – 4,156
Broadly held+74

Who Holds ENGN

Last 8 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 68 filers, like-for-like change -3.2%; actively managed books -3.2%; index-like books -34.5%.

Holder type Share Filers Change
Registered adviser 36.1% 32 -3.6%
Exempt adviser 18.4% 4 -2.9%
Adviser 2.3% 2 -63.3%
Bank 0.1% 6 -91.4%
Broker-dealer 0.1% 2 +343.3%
Non-US 0.0% 2 -19.4%
Holding company 0.0% 1 -58.0%
Unknown 42.9% 19 +10.3%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Conviction and Crowding

60 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
2
3.33% of filers hold it in their top 10
Jun 30, 2026: 3
Holders above 5%
1
median weight 0.002%
Jun 30, 2026: 1
Crowding
38.7%
of shares outstanding, 90th percentile
Jun 30, 2026: 41.5%
Private-fund advisers
37.5%
of shares outstanding
Institutional ownership
72.1%
80.3% of the estimated free float
Top 10 holders
82.5%
of 13F shares, Herfindahl 0.099
Active holders
-3.4%
like-for-like share change of active filers
5% stakes on record
8
2 13D, 6 13G (1 institutional, 5 passive, 0 exempt)
How long holders have held it value-weighted 5.3 quarters
Under 1 year 36.1% 1 to 3 years 42.0% 3 years or more 21.8% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $1,715,534 (4 buying, 4 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$5.23
estimated per share
Jun 30, 2026: $6.17
Quarter-end price
$2.00
implied by 13F values
Estimated gain or loss
-61.7%
price against the estimated cost
Estimated at a loss
87.0%
of costed 13F value

Estimated cost covers 80.1% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies ENGN's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 IMA ImageneBio, Inc. 5
2 CBIO Crescent Biopharma, Inc. 6
3 CTMX CytomX Therapeutics, Inc. 7
4 BCAX Bicara Therapeutics Inc. 5
5 PLRX Pliant Therapeutics, Inc. 5
6 OKUR OnKure Therapeutics, Inc. 5
7 OCS Oculis Holding AG 4
8 OM Outset Medical, Inc. 3
9 SEER Seer, Inc. 3
10 ZYME Zymeworks Inc. 4

Shareholder Targets

13F filers that own its peers but not ENGN, quarter ended Sep 30, 2026

Found through its holder-overlap peers: IMA, CBIO, CTMX, BCAX, PLRX, OKUR, OCS, OM, SEER, ZYME, AVIR, FHTX, BRVE, RCUS, PMVP, IMTX, ANNX, PYXS, IVVD, SPTX. 591 filers in all.

# Filer In peers
1 BlackRock, Inc. Holding company, Index-like $889,559,323 20 held
2 GILEAD SCIENCES, INC. Unknown, Concentrated $811,701,550 1 held
3 FMR LLC Holding company, Diversified active $724,788,876 17 held
4 EcoR1 Capital, LLC Registered adviser, Concentrated $616,902,918 2 held
5 VANGUARD CAPITAL MANAGEMENT LLC Registered adviser, Index-like $350,973,999 18 held
6 STATE STREET CORP Bank, Index-like $315,414,615 19 held
7 ORBIMED ADVISORS LLC Registered adviser, Diversified active $289,173,573 4 held
8 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $279,495,514 4 held
9 WELLINGTON MANAGEMENT GROUP LLP Holding company, Diversified active $218,895,894 7 held
10 a16z Capital Management, L.L.C. Registered adviser, Concentrated $206,694,884 1 held

Fund Ownership of ENGN by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 0.11% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.06% 40,733
Index ETFs 0.05% 32,625
Active ETFs 0.00% 0
Active funds 0.77% 516,217
Unclassified 0.00% 0
All registered funds 0.88% 589,575
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
14
Increased
15
Decreased
17
Sold Out
16
Unchanged
22

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: -2
Institutional value: +11.7%
Shares held: -3.2%

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 78 of 78
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open
Key facts CIK 1980845 CUSIP 29286X101 13F (30d) 59 filings 58 filers Visit website Investor relations